Hydroxyzine hydrochloride and Rinvoq drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Hydroxyzine hydrochloride (hydroxyzine hydrochloride) and Rinvoq (upadacitinib). Common drug interactions include rash among females and dermatitis atopic among males.

The phase IV clinical study analyzes what interactions people have when they take Hydroxyzine hydrochloride and Rinvoq. It is created by eHealthMe based on reports of 46 people who take the same drugs from the FDA, and is updated regularly.

What is Hydroxyzine hydrochloride?

Hydroxyzine hydrochloride has active ingredients of hydroxyzine hydrochloride. It is often used in stress and anxiety. eHealthMe is studying from 10,486 Hydroxyzine hydrochloride users. Check the latest studies of Hydroxyzine hydrochloride.

What is Rinvoq?

Rinvoq has active ingredients of upadacitinib. eHealthMe is studying from 47,375 Rinvoq users. Check the latest studies of Rinvoq.



On Jul, 12, 2026

46 people who take Hydroxyzine hydrochloride and Rinvoq together, and have interactions are studied.

Hydroxyzine hydrochloride and Rinvoq drug interactions.

What are the common drug interactions of Hydroxyzine Hydrochloride and Rinvoq, by gender? *:

female:

  1. Rash
  2. Rheumatoid arthritis (a chronic progressive disease causing inflammation in the joints)
  3. Nausea (feeling of having an urge to vomit)
  4. Staphylococcal infection (an infection with staphylococcus bacteria)
  5. Swelling
  6. Ankylosing spondylitis (type of arthritis affecting the spine)
  7. Chronic sinusitis (long lasting inflammation of the paranasal sinuses)
  8. Erythema (redness of the skin)
  9. Fatigue (feeling of tiredness)
  10. Feeling hot

male:

  1. Dermatitis atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder)
  2. Hepatic enzyme increased
  3. Increased tendency to bruise (increased tendency to injure the underlying soft tissue or bone)
  4. Limb injury
  5. Lupus-like syndrome (a disease symptom matches with lupus an immune disease)
  6. Rash papular (redness with papule)

What are the common drug interactions of Hydroxyzine Hydrochloride and Rinvoq, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Arthralgia (joint pain)
  2. Discomfort
  3. Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters)
  4. Haemarthrosis (haemarthrosis is where blood is able to enter the joint capsule)
  5. Rash

20-29:

  1. Staphylococcal infection (an infection with staphylococcus bacteria)
  2. Adverse drug reaction
  3. Cellulitis (infection under the skin)
  4. Drug tolerance decreased
  5. Hospitalisation

30-39:

  1. Lupus-like syndrome (a disease symptom matches with lupus an immune disease)
  2. Rash papular (redness with papule)

40-49:

  1. Drug ineffective

50-59:

  1. Alopecia (absence of hair from areas of the body)
  2. Arthralgia (joint pain)
  3. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  4. Dermatitis atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder)
  5. Diarrhoea
  6. Fatigue (feeling of tiredness)
  7. Hyperhidrosis (abnormally increased sweating)
  8. Ludwig angina (a type of cellulitis that involves the floor of the mouth, under the tongue)
  9. Nausea (feeling of having an urge to vomit)
  10. Pain

60+:

  1. Acute myocardial infarction (acute heart attack)
  2. Blood cholesterol increased
  3. Squamous cell carcinoma of skin (a cancer of a kind of epithelial cell, the squamous cell. these cells are the main part of the epidermis of the skin)
  4. Blood creatine phosphokinase increased
  5. Blood triglycerides increased
  6. Chronic sinusitis (long lasting inflammation of the paranasal sinuses)
  7. Drug ineffective
  8. Injection site bruising
  9. Liver disorder (liver diseases)
  10. Pneumonia

What are the existing conditions these people have? *

  1. Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 21 people, 45.65%
  2. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 17 people, 36.96%

* Approximation only. Some reports may have incomplete information.

Do you take Hydroxyzine hydrochloride and Rinvoq?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Hydroxyzine hydrochloride and Rinvoq:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Hydroxyzine hydrochloride:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Rinvoq:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Hydroxyzine hydrochloride and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Rinvoq and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on hydroxyzine hydrochloride and upadacitinib (the active ingredients of Hydroxyzine hydrochloride and Rinvoq, respectively), and Hydroxyzine hydrochloride and Rinvoq (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: